Activision Blizzard: Take Profits or Buy More Amid Microsoft's Offer?

With ATVI trading around $82 we have some room to wiggle.

Microsoft to Buy Activision Blizzard: How Traders Can Play It Into Earnings

This confirms why I cast my lot with MSFT CEO Satya Nadella in the first place.

Blackstone Poised to Become Biggest Aussie Gambling Operator

After buying in at a bargain price, the private equity firm is upping its bid for troubled Crown Resorts.

More Big Deals for Health Care Eyed in 2022

As M&A investments could hit $400 billion this year, watch for buys in health technology and data, biotech, pharma and medical devices.

You're Not Wrong Being in AT&T, It's Just Not for Me

A lot is riding on successfully pulling off the Warner Media deal.

Caution Signs Are Flashing in My Mind as the New Year Begins

The biotech sector looks ripe for staging a comeback, but a significant geopolitical event could throw the entire market for a loop.

I Don't Love Biogen, But Here's How to Trade It

I'm not saying get married to the stock, I'm saying that the idea could be a trade based on two possible catalysts.

These 2 Undervalued Biotechs Are Ripe for Acquisition

Mirum Pharmaceuticals and TG Therapeutics are undervalued as stand-alone entities, but also would make easy and logical targets for a larger player.

Why AT&T 'Fits the Mold' for Investors in 2022

The beaten-down name is finally lining up as an attractive value play.

Here's Where Oracle Is Worth a Shot

In a market filled with charts without a clear stop, ORCL offers that.